Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Luarde Montano Soto

Clinical Cardiac Electrophysiology San Juan, PR Medical Doctor

NPI 1033213368 CMS profile 92506

176 Street Edificio Cupey Plaza, Box 105, San Juan, PR 00926

Open in the dashboard

General payments

$28,744

901 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Luarde Montano Soto of San Juan, PR is reported in the CMS Open Payments database as having received $28,744 across 901 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,119 116
2024 General $5,421 132
2023 General $3,070 134
2022 General $3,641 154
2021 General $3,261 147
2020 General $2,619 58
2019 General $6,613 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luarde Montano Soto
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Luarde Montano Soto were reported at $4,119. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Luarde Montano Soto Clinical Cardiac Electrophysiology median Middle half National median
2019 $6,613 $2,361 $585–$8,260 $163
2020 $2,619 $993 $247–$4,351 $114
2021 $3,261 $1,185 $326–$4,739 $132
2022 $3,641 $2,073 $554–$6,789 $149
2023 $3,070 $2,568 $759–$8,159 $160
2024 $5,421 $2,557 $703–$7,403 $164
2025 $4,119 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $10,171 286 payments
  2. Boston Scientific Corporation $7,469 300 payments
  3. Abbott Laboratories $4,896 173 payments
  4. Janssen Pharmaceuticals, Inc $2,015 34 payments
  5. Medtronic Vascular, Inc. $1,980 24 payments
  6. Johnson and Johnson International $1,007 27 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $372 18 payments
  8. E.R. Squibb & Sons, L.L.C. $301 14 payments
  9. PBG Puerto Rico LLC $208 12 payments
  10. Pfizer Pharmaceuticals LLC $187 6 payments
  11. Other $137 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,255 880 payments
  2. Travel and Lodging $3,199 14 payments
  3. Consulting Fee $3,000 5 payments
  4. Education $290 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $2,015 34 payments
  2. MICRA Pacemakers $1,971 24 payments
  3. CLARIA MRI QUAD CRT-D SURESCAN $1,374 18 payments
  4. Micra Pacemakers $1,323 30 payments
  5. WATCHMAN $1,035 31 payments
  6. EVERA MRI XT DR SURESCAN $996 9 payments
  7. Carto 3 $853 21 payments
  8. Agilis NxT EP Introducer $836 3 payments
  9. Ensite Cardiac Mapping System $831 3 payments
  10. COBALT DR MRI SURESCAN $789 30 payments
  11. Other $16,023 664 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,723

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$418,855

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

30.9%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 299 $189,837
Xarelto Rivaroxaban Brand 269 $166,039
Entresto Sacubitril/Valsartan Brand 16 $15,177
Multaq Dronedarone Hcl Brand 14 $13,409
Flecainide Acetate Generic 331 $8,326
Amiodarone Hcl Generic 277 $8,116
Metoprolol Succinate Generic 498 $5,816
Propafenone Hcl Generic 75 $1,746
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 62 $1,270
Sotalol Sotalol Hcl Brand 74 $966

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$45,138

Medicare's payments for the services billed

Medicare patients

134

Average age 79

Services billed

453

65 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 72%
Atrial fibrillation 57%
Heart failure 51%
Arthritis 51%
Chronic kidney disease 48%
Ischemic heart disease 43%
Osteoporosis 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
$47 269 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

901 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record